News & Updates

Show Multimedia Only

Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development

21 Jun 2022 by

Children who grow in height fast appears to have a higher risk of islet autoimmunity (IAA) and rapid progression to type 1 diabetes (T1D), a study has found.

21 Jun 2022

Normal weight obesity in adolescents tied to cardiometabolic risk

21 Jun 2022

Adolescents with normal weight obesity (NMO) may present with several cardiometabolic risk factors, putting them at greater risk of developing vascular events or diabetes, suggests a recent study.

21 Jun 2022

Semaglutide reduces long-term T2D risk in overweight/obese patients

21 Jun 2022 by

Once-weekly injection of semaglutide significantly reduced the 10-year risk of developing type 2 diabetes (T2D) among overweight or obese patients, according to a post hoc analysis of the STEP* 1 and 4 trials presented at ADA 2022.

21 Jun 2022

Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths

20 Jun 2022

Insulin resistance in young people with obesity is positively associated with an atherogenic lipoprotein/lipid profile and carotid intima-media thickness (cIMT), regardless of their glucose tolerance status, suggests a study.

20 Jun 2022

Dulaglutide: A new horizon for T2D treatment in kids

18 Jun 2022 by

A once-weekly subcutaneous dose of the GLP-1* receptor agonist dulaglutide successfully controlled glycaemic levels in youths with type 2 diabetes (T2D) being treated with lifestyle modification with or without metformin or insulin, results of the multinational, phase III AWARD-PEDS** study showed.

18 Jun 2022

Novel drug safely lowers serum uric acid in hyperuricaemic patients

18 Jun 2022

Treatment with HP501, a novel renal urate transporter 1 inhibitor, effectively reduces serum uric acid (SUA) in healthy volunteers and patients with hyperuricaemia, with no serious adverse effects, according to the results of study.

18 Jun 2022

LDL-C properly managed in older T2DM patients

18 Jun 2022

Regardless of the use of medication, levels of low-density lipoprotein cholesterol (LDL-C) appear to be appropriately managed in older type 2 diabetes mellitus (T2DM) patients, contributing to the prevention of coronary artery disease (CAD), a recent study has found.

18 Jun 2022

EMPRISE shows CV efficacy, safety of empagliflozin in routine care

16 Jun 2022 by

The final analysis of the 5-year monitoring EMPRISE* programme presented at ADA 2022 demonstrated the cardiovascular (CV) efficacy of empagliflozin in patients with type 2 diabetes (T2D), with a safety profile that aligns with existing evidence.

16 Jun 2022

Concomitant insulin may counter renoprotective effects of SGLT2is in T2D patients with CKD

16 Jun 2022

Renal composite outcomes (RCO) appear to be less favourable among type 2 diabetes (T2D) patients with chronic kidney disease (CKD) treated with insulin and sodium-glucose cotransporter 2 inhibitors (SGLT2i), a recent Japan study has found.

16 Jun 2022

SGLT2 inhibitors beneficial in Chinese patients with type 2 diabetes

15 Jun 2022 by

A Singapore study has reported good real-world experience with sodium-glucose co-transporter-2 (SGLT2) inhibitors, which are well tolerated and effective at improving blood sugar and lowering complications risk.

15 Jun 2022

News & Updates

Showing Endocrinology articles

Showing

Specialty:

Rapid childhood growth rate tied to elevated risk of islet autoimmunity, T1D development

Normal weight obesity in adolescents tied to cardiometabolic risk

Semaglutide reduces long-term T2D risk in overweight/obese patients

Insulin resistance tied to atherogenic lipoprotein/lipid, cIMT in obese youths

Dulaglutide: A new horizon for T2D treatment in kids

Novel drug safely lowers serum uric acid in hyperuricaemic patients

LDL-C properly managed in older T2DM patients

EMPRISE shows CV efficacy, safety of empagliflozin in routine care

Concomitant insulin may counter renoprotective effects of SGLT2is in T2D patients with CKD

SGLT2 inhibitors beneficial in Chinese patients with type 2 diabetes